Recent advances in biological strategies for targeted drug delivery

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 3, 2009, Pages 206-221

  Ye, Xin ^a   Yang, Decheng ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Aptamer; Ligand; Nanoparticle; Polymer; Targeted drug delivery; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; APTAMER; ARGINYLGLYCYLASPARTIC ACID; CARBOHYDRATE DERIVATIVE; CARBON NANOTUBE; CHITOSAN; DENDRIMER; DOXORUBICIN; DRUG CARRIER; FOLIC ACID; INSULIN; LIGAND; LIPID; LIPOSOME; MACROGOL; NANOPARTICLE; NUCLEIC ACID; PEPTIDE DERIVATIVE; PLASMID DNA; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; SCLEROPROTEIN; SMALL INTERFERING RNA; TOSITUMOMAB I 131; UNINDEXED DRUG; VIRUS VECTOR; VITAMIN;

ACUTE GRANULOCYTIC LEUKEMIA; BIODEGRADABILITY; CHEMICAL MODIFICATION; CLINICAL TRIAL; DIABETES MELLITUS; DNA FRAGMENTATION; DNA MODIFICATION; DNA VECTOR; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TRANSPORT; ENCAPSULATION; GLIOMA; HUMAN; MACROMOLECULE; MOLECULAR BIOLOGY; NONHUMAN; NONVIRAL GENE THERAPY; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN TARGETING; PSEUDOTYPING; REVIEW; RNA DEGRADATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CELL SURFACE;

EID: 73249136334     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909789007025     Document Type: Review

References (207)

1. Neumann, E.; Schaefer-Ridder, M.; Wang, Y.; Hofschneider, P. H. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J., 1982, 1(7), 841-845.
2. Wong, T.W.; Ko, S.F.; Hui, S.W. Enhancing transdermal drug delivery with electroporation. Recent Pat. Drug Deliv. Formul., 2008, 2(1), 51-57.
3. Bodor, N.; Farag, H.H. Improved delivery through biological membranes XIV: Brain-specific, ustained delivery of testosterone using a redox chemical delivery system. J. Pharm. Sci., 1984, 73 (3), 385-389.
4. Bodor, N.; Buchwald, P. Recent advances in the brain targeting of neuropharmaceuticals by chemical delivery systems. Adv. Drug Deliv. Rev., 1999, 36 (2-3), 229-254.
5. Matte, G.; Loc, T.B.; Bernard, J. The effect of diazotization of A-methopterin with hamster γ globulin on the mouse leukaemia. Hebd. Seances Acad. Sci., 1958, 246, 1626-9.
6. Chung, J.; Kim, T.H. Integrin-dependent translational control: Implication in cancer progression. Microsc. Res. Tech., 2008, 71(5), 380-386.
7. Pabla, R.; Weyrich, A.S.; Dixon, D.A.; Bray, P.F.; McIntyre, T.M.; Prescott, S.M.; Zimmerman, G. A. Integrin-dependent control of translation: engagement of integrin alphaIIbbeta3 regulates synthesis of proteins in activated human platelets. J. Cell Biol., 1999, 144(1), 175-184.
8. Tsuruo, T.; Fujita, N. Platelet aggregation in the formation of tumor metastasis. Proc. Jpn. Acad. Ser. B. Phys. Biol. Sci., 2008, 8(6), 189-198.
9. Hallahan, D.; Geng, L.; Qu, S.; Scarfone, C.; Giorgio, T.; Donnelly, E.; Gao, X.; Clanton, J. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell, 2003, 3(1), 63-74.
10. Kumar, C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets, 2003, 4 (2), 123-31.
11. Hood, J.D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R.A.; Xiang, R.; Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature. Science, 2002, 296(5577), 2404-2407.
12. Meyer, A.; Auernheimer, J.; Modlinger, A.; Kessler, H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr. Pharm. Des., 2006, 12 (22), 2723-2447.
13. Pierschbacher, M.D.; Ruoslahti, E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 1984, 309(5963), 30-33.
14. Pierschbacher, M.D.; Ruoslahti, E. Variants of the cell recognition site of fibronectin that retain attachment-promoting activity. Proc. Natl. Acad. Sci. USA, 1984, 81(19), 5985-5988.
15. Gartner, T.K.; Bennett, J.S. The tetrapeptide analogue of the cell attachment site of fibronectin inhibits platelet aggregation and fibrinogen binding to activated platelets. J. Biol. Chem., 1985, 260 (22), 11891-11894.
16. Plow, E.F.; Pierschbacher, M.D.; Ruoslahti, E.; Marguerie, G.A.; Ginsberg, M.H. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc. Natl. Acad. Sci. USA, 1985, 82(23), 8057-8061.
17. Suzuki, S.; Oldberg, A.; Hayman, E.G.; Pierschbacher, M.D.; Ruoslahti, E. Complete amino acid sequence of human vitronectin deduced from cDNA. Similarity of cell attachment sites in vitronectin and fibronectin. EMBO J., 1985, 4(10), 2519-24.
18. Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P. Y.; Scaria, P. V.; Woodle, M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res., 2004, 32(19), e149.
19. Morse, M. Technology evaluation: Rexin-G, Epeius Biotechnologies. Curr. Opin. Mol. Ther., 2005, 7(2), 164-169.
20. Alonso, M.M.; Jiang, H.; Yokoyama, T.; Xu, J.; Bekele, N.B.; Lang, F.F.; Kondo, S.; Gomez-Manzano, C.; Fueyo, J. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol. Ther., 2008, 16(3), 487-493.
21. Galanis, E.; Carlson, S.K.; Foster, N.R.; Lowe, V.; Quevedo, F.; McWilliams, R.R.; Grothey, A.; Jatoi, A.; Alberts, S.R.; Rubin, J. Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. Mol. Ther. 2008, 16(5), 979-984.
22. Ley, K. The role of selectins in inflammation and disease. Trends Mol. Med., 2003, 9(6), 263-268.
23. Weis, W.I.; Drickamer, K. Structural basis of lectin-carbohydrate recognition. Annu. Rev. Biochem., 1996, 65, 441-473.
24. Rogers, J.C.; Kornfeld, S. Hepatic uptake of proteins coupled to fetuin glycopeptide. Biochem Biophys. Res. Commun., 1971, 45(3), 622-629.
25. Gabor, F.; Bogner, E.; Weissenboeck, A.; Wirth, M. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv. Drug Deliv. Rev., 2004, 56 (4), 459-480.
26. Baenziger, J.U.; Fiete, D. Separation of two populations of endocytic vesicles involved in receptor-ligand sorting in rat hepatocytes. J. Biol. Chem., 1986, 261(16), 7445-7754.
27. Plank, C.; Zatloukal, K.; Cotten, M.; Mechtler, K.; Wagner, E. Gene transfer into hepatocytes using asialoglycoprotein receptor mediated endocytosis of DNA complexed with an artificial tetra-antennary galactose ligand. Bioconjug. Chem., 1992, 3(6), 533-539.
28. Tan, M.C.; Mommaas, A.M.; Drijfhout, J.W.; Jordens, R.; Onder-water, J.J.; Verwoerd, D.; Mulder, A.A.; van der Heiden, A.N.; Scheidegger, D.; Oomen, L.C.; Ottenhoff, T.H.; Tulp, A.; Neefjes, J.J.; Koning, F. Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells. Eur. J. Immunol., 1997, 27(9), 2426-2435.
29. Erbacher, P.; Bousser, M.T.; Raimond, J.; Monsigny, M.; Midoux, P.; Roche, A.C. Gene transfer by DNA/glycosylated polylysine complexes into human blood monocyte-derived macrophages. Hum. Gene Ther., 1996, 7(6), 721-729.
30. Fajac, I.; Briand, P.; Monsigny, M.; Midoux, P. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Hum. Gene Ther., 1999, 10(3), 395-406.
31. Fiume, L.; Cerenzia, M.R.; Bonino, F.; Busi, C.; Mattioli, A.; Brunetto, M.R.; Chiaberge, E.; Verme, G. Inhibition of hepatitis B virus replication by vidarabine monophosphate conjugated with lactosaminated serum albumin. Lancet, 1988, 2(8601), 13-5.
32. Ponzetto, A.; Fiume, L.; Forzani, B.; Song, S.Y.; Busi, C.; Mattioli, A.; Spinelli, C.; Marinelli, M.; Smedile, A.; Chiaberge, E.; Bonino, F.; Gervasi, G.B.; Rapicetta, M.; Verme, G. Adenine arabinoside monophosphate and acyclovir monophosphate coupled to lactosaminated albumin reduce woodchuck hepatitis virus viremia at doses lower than do the unconjugated drugs. Hepatology, 1991, 14(1), 16-24.
33. Barton, N.W.; Brady, R.O.; Dambrosia, J.M.; Di Bisceglie, AM.; Doppelt, S.H.; Hill, S.C.; Mankin, H.J.; Murray, G.J.; Parker, R.I.; Argoff, C.E.; et al., Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324(21), 1464-70.
34. Andre, S.; Frisch, B.; Kaltner, H.; Desouza, D.L.; Schuber, F.; Gabius, H.J. Lectin-mediated drug targeting: selection of valency, sugar type (Gal/Lac), and spacer length for cluster glycosides as parameters to distinguish ligand binding to C-type asialoglycoprotein receptors and galectins. Pharm. Res., 2000, 17(8), 985-990.
35. Yuthavong, Y.; Kamchonwongpaisan, S.; Leartsakulpanich, U.; Chitnumsub, P. Folate metabolism as a source of molecular targets for antimalarials. Future Microbiol., 2006, 1, 113-25.
36. Thoma, N.H.; Leadlay, P.F. Mechanistic and structural studies on methylmalonyl-CoA mutase. Biochem. Soc. Trans., 1998, 26(3), 293-298.
37. Flodh, H.; Ullberg, S. Accumulation of labelled vitamin B12 in some transplanted tumours. Int. J. Cancer 1968, 3(5), 694-699.
38. Flodh, H. Autoradiographic studies on distribution of radiocobalt chloride in pregnant mice. Acta Radiol. Ther. Phys. Biol., 1968, 7(2), 121-128.
39. Blomquist, L.; Flodh, H.; Ullberg, S. Uptake of labelled vitamin B 12 and 4-iodophenylalanine in some tumors of mice. Experientia, 1969, 25(3), 294-296.
40. Bagnato, J.D.; Eilers, A.L.; Horton, R.A.; Grissom, C.B. Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin. J. Org. Chem., 2004, 69(26), 8987-8996.
41. Weinshenker, M.N.; West, G.F.; Araneo, B.A.; Li, W. Cobalamin cojugates for anti-tumor therapy. US Pat. 7232805B2, 2007.
42. Waibel, R.; Treichler, H.; Schaefer, N.G.; van Staveren, D.R.; Mundwiler, S.; Kunze, S.; Kuenzi, M.; Alberto, R.; Nuesch, J.; Knuth, A.; Moch, H.; Schibli, R.; Schubiger, P.A., New derivatives of vitamin B12 show preferential targeting of tumors. Cancer Res., 2008, 68(8), 2904-2911.
43. Carmel, R. Extreme elevation of serum transcobalamin I in patients with metastatic cancer. N. Engl. J. Med., 1975, 292(6), 282-284.
44. Chalasani, K.B.; Russell-Jones, G.J.; Yandrapu, S.K.; Diwan, P.V.; Jain, S.K. A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release, 2007, 117(3), 421-429.
45. Patterson, D. Folate metabolism and the risk of Down syndrome. Downs Syndr. Res. Pract., 2008, 12(2), 93-97.
46. Russell-Jones, G.; McTavish, K.; McEwan, J.; Rice, J.; Nowotnik, D. Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours. J. Inorg. Biochem., 2004, 98(10), 1625-1633.
47. Leamon, C.P.; Low, P.S. Folate-mediated targeting: from diagnostics to drug and gene delivery. Drug Discov. Today, 2001, 6(1), 44-51.
48. Low, P.S.; Henne, W.A.; Doorneweerd, D.D. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res., 2008, 41(1), 120-129.
49. Salazar, M.D.; Ratnam, M. The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev., 2007, 26(1), 141-152.
50. Reddy, J.A.; Allagadda, V.M.; Leamon, C.P. Targeting therapeutic and imaging agents to folate receptor positive tumors. Curr. Pharm. Biotechnol., 2005, 6(2), 131-150.
51. Lee, J.W.; Lu, J.Y.; Low, P.S.; Fuchs, P.L. Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics. Bioorg. Med. Chem., 2002, 10(7), 2397-414.
52. Aronov, O.; Horowitz, A.T.; Gabizon, A.; Gibson, D. Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem., 2003, 14(3), 563-574.
53. Atkinson, S.F.; Bettinger, T.; Seymour, LW.; Behr, J.P.; Ward, C.M. Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells. J. Biol. Chem., 2001, 276(30), 27930-27935.
54. Vlahov, I.R.; Wang, Y.; Kleindl, P.J.; Leamon, C.P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part II: Folic acid conjugates of tubulysins and their hydrazides. Bioorg. Med. Chem. Lett., 2008, 18(16), 4558-4561.
55. Vinogradov, S.V.; Mitin, A.; Warren, G. Folate-targeted polyformulations of cytotoxic nucleoside triphosphates and paclitaxel. Polymer Prepr., 2008, 49(2), 1050-1051.
56. Lee, R.J.; Low, P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem., 1994, 269(5), 3198-204.
57. Lee, R.J.; Low, P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta, 1995, 1233(2), 134-144.
58. Pan, X.Q.; Wang, H.; Lee, R.J. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm. Res., 2003, 20(3), 417-422.
59. Pan, X.Q.; Zheng, X.; Shi, G.; Wang, H.; Ratnam, M.; Lee, R.J. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood, 2002, 100(2), 594-602.
60. Lee, R.J.; Huang, L. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J. Biol. Chem., 1996, 271(14), 8481-8487.
61. Gosselin, M.A.; Guo, W.; Lee, R. J. Incorporation of reversibly cross-linked polyplexes into LPDII vectors for gene delivery. Bioconjug. Chem., 2002, 13(5), 1044-1053.
62. Wang, S.; Lee, R.J.; Cauchon, G.; Gorenstein, D.G.; Low, P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA, 1995, 92(8), 3318-3322.
63. Kam, N.W.; O'Connell, M.; Wisdom, J.A.; Dai, H. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl. Acad. Sci. USA, 2005, 102(33), 11600-11605.
64. Zempleni, J.; Wijeratne, S.S.; Hassan, Y.I. Biotin. Biofactors, 2009, 35(1), 36-46.
65. Goldenberg, D.M.; Sharkey, R.M.; Paganelli, G.; Barbet, J.; Chatal, J.F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J. Clin. Oncol., 2006, 24(5), 823-834.
66. Ojima, I. Guided molecular missiles for tumor-targeting chemotherapy-case studies using the second-generation taxoids as warheads. Acc. Chem. Res., 2008, 41(1), 108-119.
67. Low, P.S.; Kularatne, S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol., 2009, [Epub ahead of print].
68. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256(5517), 495-497.
69. Zhang, Q.; Chen, G.; Liu, X.; Qian, Q. Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy. Cell Res., 2007, 17(2), 89-99.
70. Henry, M.D.; Wen, S.; Silva, M.D.; Chandra, S.; Milton, M.; Worland, P.J. A prostate-specific membrane antigen-targeted monoclonal antibody- chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res., 2004, 64(21), 7995-8001.
71. Ma, D.; Hopf, C.E.; Malewicz, A.D.; Donovan, G.P.; Senter, P.D.; Goeckeler, W.F.; Maddon, P.J.; Olson, W.C. Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res., 2006, 12(8), 2591-2596.
72. Schliemann, C.; Neri, D., Antibody-based targeting of the tumor vasculature. Biochim. Biophys. Acta, 2007, 1776(2), 175-192.
73. Moolten, F.L.; Cooperband, S.R. Selective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cells. Science, 1970, 169(940), 68-70.
74. Carter, P.J.; Senter, P.D. Antibody-drug conjugates for cancer therapy. Cancer J., 2008, 14(3), 154-169.
75. Kiessling, L.L.; Gordon, E.J. Transforming the cell surface through proteolysis. Chem. Biol., 1998, 5(3), R49-62.
76. Ricart, A.D.; Tolcher, A.W. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat. Clin. Pract. Oncol., 2007, 4(4), 245-255.
77. Wu, A.M.; Senter, P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol., 2005, 23(9), 1137-1146.
78. Ladner, R.C. Antibodies cut down to size. Nat. Biotechnol., 2007, 25(8), 875-877.
79. Levy-Nissenbaum, E.; Radovic-Moreno, A.F.; Wang, A.Z.; Langer, R.; Farokhzad, O.C. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol., 2008, 26(8), 442-449.
80. Tuerk, C.; Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 1990, 249(4968), 505-510.
81. Ellington, A.D.; Szostak, J.W. In vitro selection of RNA molecules that bind specific ligands. Nature, 1990, 346(6287), 818-822.
82. Ulrich, H.; Trujillo, C.A.; Nery, A.A.; Alves, J.M.; Majumder, P.; Resende, R. R.; Martins, A. H. DNA and RNA aptamers: from tools for basic research towards therapeutic applications. Comb. Chem. High Throughput Screen, 2006, 9(8), 619-632.
83. Farokhzad, O.C.; Jon, S.; Khademhosseini, A.; Tran, T.N.; Lavan, D.A.; Langer, R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res., 2004, 64(21), 7668-7672.
84. Farokhzad, O.C.; Karp, J.M.; Langer, R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert. Opin. Drug Deliv., 2006, 3(3), 311-324.
85. Chu, T.C.; Marks, J.W., 3rd; Lavery, L.A.; Faulkner, S.; Rosenblum, M.G.; Ellington, A.D.; Levy, M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res., 2006, 66(12), 5989-5992.
86. Chu, T.C.; Twu, K.Y.; Ellington, A.D.; Levy, M. Aptamer mediated siRNA delivery. Nucleic Acids Res., 2006, 34(10), e73.
87. McNamara, J.O., 2nd; Andrechek, E.R.; Wang, Y.; Viles, K.D.; Rempel, R.E.; Gilboa, E.; Sullenger, B.A.; Giangrande, P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 2006, 24(8), 1005-1015.
88. Akkina, R.; Banerjea, A.; Bai, J.; Anderson, J.; Li, M. J.; Rossi, J. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res., 2003, 23(3A), 1997-2005.
89. Li, M.J.; Kim, J.; Li, S.; Zaia, J.; Yee, J.K.; Anderson, J.; Akkina, R.; Rossi, J.J. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolarlocalizing TAR decoy. Mol. Ther., 2005, 12(5), 900-909.
90. Chan, M.Y.; Cohen, M.G.; Dyke, C.K.; Myles, S.K.; Aberle, L.G.; Lin, M.; Walder, J.; Steinhubl, S. R.; Gilchrist, I.C.; Kleiman, N.S.; Vorchheimer, D.A.; Chronos, N.; Melloni, C.; Alexander, J.H.; Harrington, R.A.; Tonkens, R.M.; Becker, R.C.; Rusconi, C.P. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation, 2008, 117(22), 2865-2874.
91. Cosmi, B. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or anti-thrombotic agent. Curr. Opin. Mol. Ther., 2009, 11(3), 322-328.
92. Gui, J.; Moyana, T.; Xiang, J. Selection of a peptide with affinity for the tumor-associated TAG72 antigen from a phage-displayed library. Biochem. Biophys. Res. Commun., 1996, 218(1), 414-419.
93. Gui, J.; Moyana, T.; Malcolm, B.; Xiang, J. Identification of a decapeptide with the binding reactivity for tumor-associated TAG72 antigen from a phage displayed library. Proteins, 1996, 24(3), 352-358.
94. Peletskaya, E.N.; Glinsky, G.; Deutscher, S.L.; Quinn, T.P. Identification of peptide sequences that bind the Thomsen-Friedenreich cancer-associated glycoantigen from bacteriophage peptide display libraries. Mol. Divers., 1996, 2(1-2), 13-18.
95. Smith, G.P.; Petrenko, V.A. Phage Display. Chem. Rev., 1997, 97(2), 391-410.
96. Koivunen, E.; Arap, W.; Rajotte, D.; Lahdenranta, J.; Pasqualini, R. Identification of receptor ligands with phage display peptide libraries. J. Nucl. Med., 1999, 40(5), 883-888.
97. Marasco, D.; Perretta, G.; Sabatella, M.; Ruvo, M. Past and future perspectives of synthetic peptide libraries. Curr. Protein Pept. Sci., 2008, 9(5), 447-467.
98. Brown, K.C. New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. Curr. Opin. Chem. Biol., 2000, 4(1), 16-21.
99. Newton, J.; Deutscher, S.L. Phage peptide display. Handb. Exp. Pharmacol., 2008, (185 Pt 2), 145-163.
100. unen, E.; Wang, B.; Ruoslahti, E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N Y) 1995, 13(3), 265-270.
101. ualini, R.; Koivunen, E.; Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 1997, 15(6), 542-546.
102. Doorbar, J.; Winter, G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J. Mol. Biol., 1994, 244(4), 361-369.
103. Oyama, T.; Sykes, K.F.; Samli, K.N.; Minna, J.D.; Johnston, S.A.; Brown, K.C. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett., 2003, 202(2), 219-230.
104. McGuire, M.J.; Samli, K.N.; Chang, Y.C.; Brown, K.C. Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp. Hematol., 2006, 34(4), 443-452.
105. Oyama, T.; Rombel, I.T.; Samli, K.N.; Zhou, X.; Brown, K.C. Isolation of multiple cell-binding ligands from different phage displayedpeptide libraries. Biosens. Bioelectron., 2006, 21(10), 1867-1875.
106. McGuire, M.J.; Samli, K.N.; Johnston, S.A.; Brown, K.C. In vitro selection of a peptide with high selectivity for cardiomyocytes in vivo. J. Mol. Biol., 2004, 342(1), 171-82.
107. Samli, K.N.; McGuire, M.J.; Newgard, C.B.; Johnston, S.A.; Brown, K.C. Peptide-mediated targeting of the islets of Langerhans. Diabetes, 2005, 54(7), 2103-2108.
108. Stewart, K.M.; Horton, K.L.; Kelley, S.O. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org. Biomol. Chem., 2008, 6(13), 2242-2255.
109. Shadidi, M.; Sioud, M. Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J., 2003, 17(2), 256-258.
110. Song, S.; Liu, D.; Peng, J.; Sun, Y.; Li, Z.; Gu, J. R.; Xu, Y. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int. J. Pharm., 2008, 363(1-2), 155-161.
111. Lo, A.; Lin, C.T.; Wu, H.C. Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Ther., 2008, 7(3), 579-589.
112. Baines, I.C.; Colas, P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov. Today, 2006, 11(7-8), 334-41.
113. Jabbari, E., Targeted delivery with peptidomimetic conjugated self-assembled nanoparticles. Pharm. Res. 2009, 26(3), 612-630.
114. Malafaya, P.B.; Silva, G.A.; Reis, R.L. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev., 2007, 59(4-5), 207-233.
115. Vorhies, J.S.; Nemunaitis, J.J. Synthetic vs. natural/ biodegradable polymers for delivery of shRNA-based cancer therapies. Methods Mol. Biol., 2009, 480, 11-29.
116. Dufes, C.; Uchegbu, I.F.; Schatzlein, A.G. Dendrimers in gene delivery. Adv. Drug Deliv. Rev., 2005, 57(15), 2177-202.
117. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applications-- reflections on the field. Adv. Drug Deliv. Rev., 2005, 57(15), 2106-2129.
118. Barrett, T.; Ravizzini, G.; Choyke, P.L.; Kobayashi, H. Dendrimers in medical nanotechnology. IEEE Eng. Med. Biol. Mag., 2009, 28(1), 12-22.
119. Jansen, J.F.; de Brabander-van den Berg, E.M.; Meijer, E.W. Encapsulation of guest molecules into a dendritic box. Science, 1994, 266(5188), 1226-1229.
120. Satija, J.; Gupta, U.; Jain, N.K. Pharmaceutical and biomedical potential of surface engineered dendrimers. Crit. Rev. Ther. Drug Carrier Syst., 2007, 24(3), 257-306.
121. Bhadra, D.; Bhadra, S.; Jain, S.; Jain, N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm., 2003, 257(1-2), 111-24.
122. Kojima, C.; Kono, K.; Maruyama, K.; Takagishi, T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem., 2000, 11(6), 910-917.
123. Tsutsumi, T.; Hirayama, F.; Uekama, K.; Arima, H. Potential use of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for short hairpin RNA-expressing plasmid DNA. J. Pharm. Sci., 2008, 97(8), 3022-3034.
124. Paleos, C.M.; Tziveleka, L.A.; Sideratou, Z.; Tsiourvas, D. Gene delivery using functional dendritic polymers. Expert Opin. Drug Deliv., 2009, 6(1), 27-38.
125. Majoros, I.J.; Thomas, T.P.; Mehta, C.B.; Baker, J.R., Jr. Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J. Med. Chem., 2005, 48(19), 5892-5899.
126. Theoharis, S.; Krueger, U.; Tan, P.H.; Haskard, D.O.; Weber, M.; George, A.J. Targeting gene delivery to activated vascular endothelium using anti E/P-Selectin antibody linked to PAMAM dendrimers. J. Immunol. Methods, 2009, 343(2), 79-90.
127. Wightman, L.; Kircheis, R.; Rossler, V.; Carotta, S.; Ruzicka, R.; Kursa, M.; Wagner, E. Different behavior of branched and linear polyethylenimine for gene delivery in vitro and in vivo. J. Gene Med., 2001, 3(4), 362-372.
128. Petersen, H.; Fechner, P.M.; Martin, A.L.; Kunath, K.; Stolnik, S.; Roberts, C.J.; Fischer, D.; Davies, M.C.; Kissel, T. Polyethylenimine-graft- poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system. Bioconjug. Chem., 2002, 13(4), 845-854.
129. Fischer, D.; Bieber, T.; Li, Y.; Elsasser, H.P.; Kissel, T. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res., 1999, 16(8), 1273-1279.
130. von Harpe, A.; Petersen, H.; Li, Y.; Kissel, T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control. Release, 2000, 69(2), 309-322.
131. Kunath, K.; von Harpe, A.; Fischer, D.; Petersen, H.; Bickel, U.; Voigt, K.; Kissel, T. Low-molecular-weight polyethylenimine as a non-viral vector for DNA delivery: comparison of physicochemical properties, transfection efficiency and in vivo distribution with high-molecular-weight polyethylenimine. J. Control. Release, 2003, 89(1), 113-25.
132. Godbey, W.T.; Wu, K.K.; Mikos, A.G. Size matters: molecular weight affects the efficiency of poly(ethylenimine) as a gene delivery vehicle. J. Biomed. Mater Res., 1999, 45(3), 268-275.
133. Furgeson, D.Y.; Chan, W.S.; Yockman, J.W.; Kim, S.W. Modified linear polyethylenimine-cholesterol conjugates for DNA complexation. Bioconjug. Chem., 2003, 14(4), 840-847.
134. Hwa Kim, S.; Hyeon Lee, S.; Tian, H.; Chen, X.; Gwan Park, T. Prostate cancer cell-specific VEGF siRNA delivery system using cell targeting peptide conjugated polyplexes. J. Drug Target, 2009, 1-7.
135. Rodriguez-Hernandez, J.; Gatti, M.; Klok, H.A. Highly branched poly(L-lysine). Biomacromolecules, 2003, 4(2), 249-258.
136. Yamagata, M.; Kawano, T.; Shiba, K.; Mori, T.; Katayama, Y.; Niidome, T. Structural advantage of dendritic poly(L-lysine) for gene delivery into cells. Bioorg. Med. Chem., 2007, 15(1), 526-532.
137. Choi, Y.H.; Liu, F.; Kim, J.S.; Choi, Y.K.; Park, J.S.; Kim, S.W. Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J. Control. Release, 1998, 54(1), 39-48.
138. Lochmann, D.; Jauk, E.; Zimmer, A. Drug delivery of oligonucleotides by peptides. Eur. J. Pharm. Biopharm., 2004, 58(2), 237-251.
139. Wattendorf, U.; Coullerez, G.; Voros, J.; Textor, M.; Merkle, H.P. Mannose-based molecular patterns on stealth microspheres for receptor-specific targeting of human antigen-presenting cells. Langmuir., 2008, 24(20), 11790-802.
140. Mousazadeh, M.; Palizban, A.; Salehi, R.; Salehi, M. Gene delivery to brain cells with apoprotein E derived peptide conjugated to polylysine (apoEdp-PLL). J. Drug Target, 2007, 15(3), 226-230.
141. Joselevich, E. Electronic structure and chemical reactivity of carbon nanotubes: a chemist's view. Chemphyschem, 2004, 5(5), 619-624.
142. Danailov, D.; Keblinski, P.; Nayak, S.; Ajayan, P. M. Bending properties of carbon nanotubes encapsulating solid nanowires. J. Nanosci. Nanotechnol., 2002, 2(5), 503-507.
143. Chattopadhyay, J.; Cortez, F.J.; Chakraborty, S.; Slater, N.K.H.; Billups, W.E. Synthesis of water-soluble pegylated single-walled carbon nanotubes. Chem. Mater., 2006, 18(25), 5864-5868.
144. Bettinger, H.F. Addition of carbenes to the sidewalls of single-walled carbon nanotubes. Chemistry, 2006, 12(16), 4372-4379.
145. Foldvari, M.; Bagonluri, M. Carbon nanotubes as functional excipients for nanomedicines: II. Drug delivery and biocompatibility issues. Nanomedicine, 2008, 4(3), 183-200.
146. Prato, M.; Kostarelos, K.; Bianco, A. Functionalized carbon nanotubes in drug design and discovery. Acc. Chem. Res., 2008, 41(1), 60-68.
147. McDevitt, M.R.; Chattopadhyay, D.; Kappel, B.J.; Jaggi, J.S.; Schiffman, S.R.; Antczak, C.; Njardarson, J.T.; Brentjens, R.; Scheinberg, D.A. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J. Nucl. Med., 2007, 48(7), 1180-1189.
148. Chandy, T.; Sharma, C.P. Chitosan-as a biomaterial. Biomater. Artif. Cells Artif. Organs, 1990, 18(1), 1-24.
149. Schipper, N.G.; Varum, K.M.; Artursson, P. Chitosans as absorption enhancers for poorly absorbable drugs. 1: Influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res., 1996, 13(11), 1686-1692.
150. Borchard, G. Chitosans for gene delivery. Adv. Drug Deliv. Rev., 2001, 52(2), 145-150.
151. Smith, J.; Wood, E.; Dornish, M. Effect of chitosan on epithelial cell tight junctions. Pharm. Res., 2004, 21(1), 43-49.
152. Jayakumar, R.; Nwe, N.; Tokura, S.; Tamura, H. Sulfated chitin and chitosan as novel biomaterials. Int. J. Biol. Macromol., 2007, 40(3), 175-181.
153. Werle, M.; Bernkop-Schnurch, A. Thiolated chitosans: useful excipients for oral drug delivery. J. Pharm. Pharmacol., 2008, 60(3), 273-281.
154. Vinsova, J.; Vavrikova, E. Recent advances in drugs and prodrugs design of chitosan. Curr. Pharm. Des., 2008, 14(13), 1311-1326.
155. Kim, T.H.; Jiang, H.L.; Nah, J.W.; Cho, M.H.; Akaike, T.; Cho, C.S. Receptor-mediated gene delivery using chemically modified chitosan. Biomed. Mater., 2007, 2(3), S95-S100.
156. Li, F.R.; Yan, W.H.; Guo, Y.H.; Qi, H.; Zhou, H.X. Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer. Int. J. Hyperthermia., 2009, 1-9, [Epub ahead of print].
157. Wilson, B.; Samanta, M.K.; Santhi, K.; Sampath Kumar, K.P.; Ramasamy, M.; Suresh, B. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease. J. Neurosci. Methods, 2009, 177(2), 427-433.
158. Olsen, D.; Yang, C.; Bodo, M.; Chang, R.; Leigh, S.; Baez, J.; Carmichael, D.; Perala, M.; Hamalainen, E.R.; Jarvinen, M.; Polarek, J. Recombinant collagen and gelatin for drug delivery. Adv. Drug Deliv. Rev., 2003, 55(12), 1547-1567.
159. Sano, A.; Maeda, M.; Nagahara, S.; Ochiya, T.; Honma, K.; Itoh, H.; Miyata, T.; Fujioka, K. Atelocollagen for protein and gene delivery. Adv. Drug Deliv. Rev., 2003, 55(12), 1651-1677.
160. Wang, J.; Lee, I.L.; Lim, W.S.; Chia, S.M.; Yu, H.; Leong, K.W.; Mao, H.Q. Evaluation of collagen and methylated collagen as gene carriers. Int. J. Pharm., 2004, 279(1-2), 115-26.
161. Matsumoto, G.; Kushibiki, T.; Kinoshita, Y.; Lee, U.; Omi, Y.; Kubota, E.; Tabata, Y. Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci., 2006, 97(4), 313-321.
162. Young, S.; Wong, M.; Tabata, Y.; Mikos, A.G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Control. Release, 2005, 109(1-3), 256-274.
163. Black, L.W. DNA packaging in dsDNA bacteriophages. Annu. Rev. Microbiol., 1989, 43, 267-292.
164. Guo, P. X.; Erickson, S.; Anderson, D. A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science, 1987, 236(4802), 690-694.
165. Lee, J.Y.; Irmiere, A.; Gibson, W. Primate cytomegalovirus assembly: evidence that DNA packaging occurs subsequent to B capsid assembly. Virology, 1988, 167(1), 87-96.
166. Reid, R.J.; Zhang, F.; Benson, S.; Anderson, D. Probing the structure of bacteriophage phi 29 prohead RNA with specific mutations. J. Biol. Chem., 1994, 269(28), 18656-18661.
167. Hoeprich, S.; Zhou, Q.; Guo, S.; Shu, D.; Qi, G.; Wang, Y.; Guo, P. Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther., 2003, 10(15), 1258-1267.
168. Hoeprich, S.; Guo, P. Computer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motor. J. Biol. Chem., 2002, 277(23), 20794-20803.
169. Guo, P. Bacterial virus phi29 DNA-packaging motor and its potential applications in gene therapy and nanotechnology. Methods Mol. Biol., 2005, 300, 285-324.
170. Guo, P. RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J. Nanosci. Nanotechnol., 2005, 5(12), 1964-1982.
171. Manjunath, N.; Wu, H.; Subramanya, S.; Shankar, P. Lentiviral delivery of short hairpin RNAs. Adv. Drug Deliv. Rev., 2009.
172. Wang, Q.Z.; Lv, Y.H.; Diao, Y.; Xu, R. The design of vectors for RNAi delivery system. Curr. Pharm. Des., 2008, 14(13), 1327-1340.
173. Arnberg, N. Adenovirus receptors: implications for tropism, treatment and targeting. Rev. Med. Virol., 2009, 19(3), 165-178.
174. Kuhlmann, K.F.; Gouma, D.J.; Wesseling, J.G. Adenoviral gene therapy for pancreatic cancer: where do we stand? Dig. Surg., 2008, 25(4), 278-292.
175. Koizumi, N.; Mizuguchi, H.; Utoguchi, N.; Watanabe, Y.; Hayakawa, T. Generation of fiber-modified adenovirus vectors contain ing heterologous peptides in both the HI loop and C terminus of the fiber knob. J. Gene Med., 2003, 5(4), 267-276.
176. Jacob, D.; Davis, J.J.; Zhang, L.; Zhu, H.; Teraishi, F.; Fang, B. Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter. Cancer Gene Ther., 2005, 12(2), 109-115.
177. Mizuguchi, H.; Hayakawa, T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther., 2002, 9(3), 236-242.
178. Lecollinet, S.; Gavard, F.; Havenga, M. J.; Spiller, O. B.; Lemckert, A.; Goudsmit, J.; Eloit, M.; Richardson, J. Improved gene delivery to intestinal mucosa by adenoviral vectors bearing subgroup B and d fibers. J. Virol., 2006, 80(6), 2747-2759.
179. Kuhlmann, K.F.; van Geer, M.A.; Bakker, C.T.; Dekker, J.E.; Havenga, M.J.; Elferink, R.P.; Gouma, D.J.; Bosma, P.J.; Wesseling, J.G. Fiber-chimeric adenoviruses expressing fibers from serotype 16 and 50 improve gene transfer to human pancreatic adenocarcinoma. Cancer Gene Ther., 2009.
180. Stoff-Khalili, M.A.; Rivera, A.A.; Glasgow, J.N.; Le, L.P.; Stoff, A.; Everts, M.; Tsuruta, Y.; Kawakami, Y.; Bauerschmitz, G.J.; Mathis, J.M.; Pereboeva, L.; Seigal, G.P.; Dall, P.; Curiel, D.T. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther., 2005, 12(23), 1696-706.
181. Krasnykh, V.; Belousova, N.; Korokhov, N.; Mikheeva, G.; Curiel, D.T. Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol., 2001, 75(9), 4176-83.
182. Belousova, N.; Korokhov, N.; Krendelshchikova, V.; Simonenko, V.; Mikheeva, G.; Triozzi, P. L.; Aldrich, W.A.; Banerjee, P.T.; Gillies, S.D.; Curiel, D.T.; Krasnykh, V. Genetically targeted adenovirus vector directed to CD40-expressing cells. J. Virol., 2003, 77(21), 11367-11377.
183. Eto, Y.; Yoshioka, Y.; Mukai, Y.; Okada, N.; Nakagawa, S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm., 2008, 354(1-2), 3-8.
184. Wesseling, J.G.; Bosma, P.J.; Krasnykh, V.; Kashentseva, E.A.; Blackwell, J.L.; Reynolds, P. N.; Li, H.; Parameshwar, M.; Vickers, S.M.; Jaffee, E.M.; Huibregtse, K.; Curiel, D.T.; Dmitriev, I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 2001, 8(13), 969-976.
185. Eto, Y.; Gao, J.Q.; Sekiguchi, F.; Kurachi, S.; Katayama, K.; Maeda, M.; Kawasaki, K.; Mizuguchi, H.; Hayakawa, T.; Tsutsumi, Y.; Mayumi, T.; Nakagawa, S. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med., 2005, 7(5), 604-612.
186. Lanciotti, J.; Song, A.; Doukas, J.; Sosnowski, B.; Pierce, G.; Gregory, R.; Wadsworth, S.; O'Riordan, C. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol. Ther., 2003, 8(1), 99-107.
187. Ogawara, K.; Kuldo, J.M.; Oosterhuis, K.; Kroesen, B.J.; Rots, M.G.; Trautwein, C.; Kimura, T.; Haisma, H.J.; Molema, G. Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res. Ther., 2006, 8(1), R32.
188. Wong, L.F.; Azzouz, M.; Walmsley, L.E.; Askham, Z.; Wilkes, F.J.; Mitrophanous, K.A.; Kingsman, S.M.; Mazarakis, N.D. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol. Ther., 2004, 9(1), 101-11.
189. Kumar, P.; Wu, H.; McBride, J.L.; Jung, K.E.; Kim, M.H.; Davidson, B.L.; Lee, S.K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448(7149), 39-43.
190. Yang, H.; Joo, K.I.; Ziegler, L.; Wang, P. Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule. Pharm. Res., 2009, 26(6), 1432-1445.
191. Morizono, K.; Xie, Y.; Ringpis, G.E.; Johnson, M.; Nassanian, H.; Lee, B.; Wu, L.; Chen, I.S. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med., 2005, 11(3), 346-352.
192. Ziegler, L.; Yang, L.; Joo, K.; Yang, H.; Baltimore, D.; Wang, P. Targeting lentiviral vectors to antigen-specific immunoglobulins. Hum. Gene Ther., 2008, 19(9), 861-872.
193. Yang, L.; Yang, H.; Rideout, K.; Cho, T.; Joo, K. I.; Ziegler, L.; Elliot, A.; Walls, A.; Yu, D.; Baltimore, D.; Wang, P. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat. Biotechnol., 2008, 26(3), 326-334.
194. Pariente, N.; Mao, S.H.; Morizono, K.; Chen, I.S. Efficient targeted transduction of primary human endothelial cells with dual-targeted lentiviral vectors. J. Gene Med., 2008, 10(3), 242-248.
195. Pariente, N.; Morizono, K.; Virk, M.S.; Petrigliano, F.A.; Reiter, R.E.; Lieberman, J.R.; Chen, I. S. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol. Ther., 2007, 15(11), 1973-1981.
196. van Hooijdonk, L.W.; Ichwan, M.; Dijkmans, T.F.; Schouten, T.G.; de Backer, M.W.; Adan, R. A.; Verbeek, F.J.; Vreugdenhil, E.; Fitzsimons, C.P. Lentivirus-mediated transgene delivery to the hippocampus reveals sub-field specific differences in expression. BMC Neurosci., 2009, 10, 2.
197. Kuroda, H.; Kutner, R.H.; Bazan, N.G.; Reiser, J. A comparative analysis of constitutive and cell-specific promoters in the adult mouse hippocampus using lentivirus vector-mediated gene transfer. J. Gene Med., 2008, 10(11), 1163-1175.
198. Glover, C.P.; Bienemann, A.S.; Hopton, M.; Harding, T.C.; Kew, J.N.; Uney, J.B. Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used. J. Gene Med., 2003, 5(7), 554-559.
199. Gou, D.; Narasaraju, T.; Chintagari, N.R.; Jin, N.; Wang, P.; Liu, L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucleic Acids Res., 2004, 32(17), e134.
200. R.; Shaish, A.; Rofe, K.; Feige, E.; Varda-Bloom, N.; Afek, A.; Barshack, I.; Bangio, LHodish, I.; Greenberger, S.; Peled, M.; Breitbart, E.; Harats, D. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Mol. Ther., 2008, 16(12), 1927-1936.
201. dish, I.; Tal, R.; Shaish, A.; Varda-Bloom, N.; Greenberger, S.; Rauchwerger, A.; Breitbart, E.; Bangio, L.; Ben-Shushan, D.; Pfeffer, R.; Feder, B.; Waitsman, A.; Barshack, I.; Goldberg, I.; Mazaki-Tovi, S.; Peled, M.; Harats, D. Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSVTK. Cancer Biol. Ther., 2009, 8(5), 424-432.
202. Su, H.; Joho, S.; Huang, Y.; Barcena, A.; Arakawa-Hoyt, J.; Grossman, W.; Kan, Y.W. Adeno-associated viral vector delivers cardiacspecific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc Natl. Acad. Sci. USA, 2004, 101(46), 16280-16285.
203. Cross, K.J.; Bomsztyk, E.D.; Weinstein, A.L.; Teo, E.H.; Spector, J.A.; Lyden, D.C. A novel method for targeted gene therapy in ischemic tissues through viral transfection of an expression cassette containing multiple repetitions of hypoxia response element. Plast. Reconstr. Surg., 2009, 123(2 Suppl), 76S-82S.
204. Ginn, S.L.; Cunningham, S.C.; Zheng, M.; Spinoulas, A.; Carpenter, K.H.; Alexander, I.E. In vivo assessment of mutations in OTC for dominant-negative effects following rAAV2/8-mediated gene delivery to the mouse liver. Gene Ther., 2009, 6(6), 820-823.
205. Jackson, C.A.; Messinger, J.; Peduzzi, J.D.; Ansardi, D.C.; Morrow, C.D. Enhanced functional recovery from spinal cord injury following intrathecal or intramuscular administration of poliovirus replicons encoding IL-10. Virology, 2005, 336(2), 173-83.
206. Perri, S.; Greer, C.E.; Thudium, K.; Doe, B.; Legg, H.; Liu, H.; Romero, R.E.; Tang, Z.; Bin, Q.; Dubensky, T.W., Jr.; Vajdy, M.; Otten, G.R.; Polo, J.M. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol., 2003, 77(19), 10394-10403.
207. Meyer, R.G.; Meyer-Ficca, M.L.; Kaiser, H.; Selinka, H.C.; Kandolf, R.; Kupper, J.H. Plasmid-based generation of recombinant coxsackievirus B3 particles carrying capsid gene replacement replicons. Virus Res., 2004, 104(1), 17-26.